Background. We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is given. Methods. This study aimed to determine the safety and efficacy of 32 doses of BTZ (1.3 mg/m 2 of body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against their intended living donor. Results. Dose reduction was needed in 2 patients and 2 others completely discontinued therapy for adverse events. Anti-HLA antibodies mean fluorescence intensity (MFI) values were stable prior to BTZ (P = 0.96) but decreased after therapy (mean decrease of 1916 [SE, 425] MFI, P < 0.01). No patient developed a negative crossmatch against their original intended donor, and the calculated panel-reactive antibodies based on MFI of 2000, 4000, and 8000 was unchanged in all patients. Conclusions. These data suggest that 32 doses of BTZ monotherapy was not well tolerated and resulted in only a modest reduction in anti-HLA antibodies.
D
onor-specific antibodies (DSA) are a major barrier to successful kidney transplant (KTx) and are associated with an increased risk of early and late antibody associated graft loss. Avoiding DSA is especially difficult in highly sensitized transplant candidates with calculated panel-reactive antibodies (cPRA) greater than 90%. Intense efforts to increase transplantation for these patients including kidney paired donation and priority for compatible deceased donor organs have been successful, but are not adequate. Currently, 6% of patients on the KTx waiting list have a cPRA of 100%. 1 The current therapy available to decrease alloantibody is largely ineffective, and positive crossmatch kidney transplantation is associated with antibody mediated rejection and early allograft loss. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Donor-specific antibodies also is a problem for other solid organ transplantation including heart, lung, and pancreas transplant candidates. Thus, developing therapy to decrease alloantibody production for the highly sensitized patient is a major unmet need in organ transplantation.
We and others have hypothesized that treatment with the proteasome inhibitor bortezomib (BTZ) might deplete antibodysecreting long-lived plasma cells and have an impact on DSA production. [12] [13] [14] We demonstrated in vitro that proteasome inhibition using BTZ caused apoptosis of bone marrowderived plasma cells. 15 In a pilot clinical study, we found that up to 16 doses of BTZ depleted bone marrow plasma cells, but the effect on serum alloantibody was modest. 16 Based on these encouraging, but limited results, we hypothesized that more doses of BTZ were needed for a meaningful reduction in antibody. Thus, the aim of this study was to evaluate the efficacy and safety of 32 doses of BTZ in highly sensitized KTx candidates.
MATERIALS AND METHODS

Study Design
This was a prospective, open-labeled, nonrandomized, trial conducted with informed consent using a protocol approved by the institutional review board of Mayo Foundation and Clinic, Rochester, Minnesota (institutional review board approval numbers 08-000556 and 15-002637; protocol number X05261; ClinicalTrials.gov Identifier: NCT00722722). The patients in this study met the following criteria: (1) B-cell flow cytometric cross match channel shift (BFXM) of greater than 300 against their intended living donor, (2) Table S1 (SDC, http://links.lww.com/TP/B309) for exclusion criteria.
The primary endpoint was the reduction in serum alloantibody levels following BTZ treatment to reach a BFXM of less than 300.
Desensitization Schedule
Bortezomib was given in cycles (4 doses = 1 cycle). The initial dose for all patients was 1.3 mg/m 2 body surface area (BSA) intravenously on days 1, 4, 8, and 11 with at least 10 days in between the last dose of a cycle and the first dose of the next cycle ( Figure 1 ). The dose administered remained the same throughout each cycle unless an adverse event occurred. No dose adjustment was made for renal function. We planned to give up to 8 cycles of BTZ (32 doses) unless the patient received a transplant.
Adverse Events Assessment
After each BTZ dose, patients had a complete physical examination with emphasis on the neurological evaluation to detect potential toxicities, and adverse event data were collected prospectively. Patients also had to complete a Functional Assessment of Cancer Therapy Scale/Gynecologic Oncology Group-Neurotoxicity questionnaire. 17 Toxicities were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0.
18 All previously established or new toxicities observed any time (with the exception of neuropathic pain and peripheral sensory neuropathy), were managed according to recommendations by the manufacturer as outlined in Table S2 (SDC, http://links.lww.com/TP/B309). Bortezomib-related neuropathic pain and/or peripheral sensory neuropathy were managed as presented in Table S3 (SDC, http://links.lww. com/TP/B309).
Alloantibody Quantification
The T and B flow cytometric crossmatch (TFXM, BFXM) and SAB (LABScreen; One Lambda, Canoga Park, CA) assays that we used have been previously described. 19 Single-antigen bead assays were obtained before and after BTZ monotherapy. Single-antigen bead assay results following any other therapy (ie, plasmapheresis) were not included in this analysis. Single serum dilutions (1/8) were performed at least once pretreatment and posttreatment to detect prozone phenomenon.
Single-antigen bead assay results from solid phase assays are semiquantitative and yield multiple data points. Detecting a meaningful change in alloantibody is difficult, and thus we examined several measures including: (1) variables; this information was analyzed using t tests, paired or unpaired, according to the data compared.
A linear mixed model in the form of a segmented regression was used to evaluate significance of treatment effect on MFI while controlling for time. 21, 22 In this case, the first time point posttreatment centers the time scale for the mixed model. Therefore, time pretreatment was recorded as negative time. The fixed effects used were time, treatment, and time posttreatment (equal to zero before treatment and simply time after treatment). Random effects were used to control for alloantibody specificity and repeated measures on patients. The same model structure was also used to analyze treatment effect within class I and class II alloantibodies. Data points of MFI versus time were averaged over patient and alloantibody specificity at each time point. Superimposed lines are associated with the respective slopes and intercepts for the fixed effects in the segmented regression formula. Mean alloantibody levels before and after treatment as well as average treatment effect are given as parameter estimates corresponding to intercepts and the slope associated with the categorical treatment variable. Therefore, these are summarized as parameter estimate and SE. A P value of 0.05 or less was considered statistically significant.
All analyses were carried out using JMP Pro 10.0 and SAS 9.4 (SAS Inst., Cary, NC). Plots of the mixed effects models were created using the R statistical package (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Study Population
Most patients were women (7/10; 70%) and had at least 1 previous KTx (8/10; 80%). The most common cause of end stage renal disease was glomerulonephritis (5/10; 50%), and the mean age at enrollment was 39.5 (SD, 6.6) years (Table 1) . The baseline BFXM mean channel shift was 532 (SD, 78), and 90% (9/10) of patients had both anti-HLA class I and class II antibodies. The mean cPRA 2000 before treatment was 98.2% (SD, 3.5).
Tolerability
Five patients (50%) completed the 32-dose regimen without dose reduction or discontinuation. One patient (10%) received a positive crossmatch KTx (BFXM of 431 post-BTZ monotherapy and 273 following plasmapheresis prior to transplant) after dose 20, and BTZ was discontinued. Dose reduction was required in 2 patients who developed severe peripheral neuropathy but eventually completed the 32-dose course. In one of these cases, the severe neuropathy was manifested by left scapular myofascial pain and upper extremity edema. Bortezomib was suspended for 9 months before restarting at 1 mg/m 2 BSA. The other patient experienced progressive severe bilateral lower extremity neuropathy, anorexia, and insomnia. Bortezomib was held for 42 days and restarted at 1 mg/m 2 BSA. Two patients (20%) discontinued therapy prior to the planned 32 doses for adverse effects. One patient stopped after 16 doses for personal reasons and severe fatigue. The other patient developed disseminated varicella zoster, severe local herpes recurrence, peritonitis in the setting of peritoneal dialysis, encephalopathy, ataxia, and visual hallucinations which required hospitalization. Bortezomib was initially discontinued for 38 days and restarted at 1 mg/m 2 BSA. The drug was again reduced to 0.7 mg/m 2 BSA but eventually stopped after 24 doses for peripheral neuropathy. Other commonly observed BTZ-related toxicities are presented in Table S4 (SDC, http://links.lww.com/TP/B309).
Effect of BTZ on Individual Anti-HLA Specificities
We compared the pretreatment and posttreatment MFIs of a random representative sample of anti-HLA antibodies (nonprozone) using a linear mixed model. We used data from a mean of 6.9 (SD, 4.1) pretreatment assays, and 4.8 (SD, 6.5) posttreatment assays obtained from a mean of 484 (SD, 328) days before BTZ (pretreatment) and a mean of 274 (SD, 484) days after completion of BTZ (posttreatment). A mean of 5.0 (SD, 1.2) individual class I specificities and 4.4 (SD, 1.6) class II specificities were compared per patient.
In this representative sample, the MFIs of individual specificities were stable pretreatment P = 0.96, but decreased posttreatment P < 0.01 (Figure 2A ). The mean decrease in MFI overall was 1916 (SE, 425). Both anti-class I and anti-class II antibodies decreased (P = 0.02 and P = 0.03, respectively) with baseline MFI in the 2000 to 8000 or greater than 8000 range (class I: MFI 2000-8000, P < 0.01; MFI > 8000, P < 0.01 and class II: MFI 2000 to 8000, P < 0.01; MFI > 8000, P < 0.01). There was also a numeric reduction in MFI in specificities with baseline MFI less than 2000, but this did not reach statistical significance (P = 0.44 for class I and P = 0.54 for class II) ( Figure 2B ). The mean BFXM decreased from 532 (SD, 78) pretreatment to 465 (SD, 90) posttreatment (P = 0.02) toward their original intended donor; but no patient reached a BFXM of less than 300. The mean TFXM remained unchanged from 270 (SD, 199) to 259 (SD, 197) (P = 0.58).
Transplant Outcomes
Eight (80%) of 10 of the treated patients received a KTx at a mean of 938 (SD, 566) days post-BTZ (16 doses = 1, Three of the transplants (37.5%) were negative crossmatch from deceased donors, whereas 5 (62.5%) were positive crossmatch. Of the positive crossmatch transplants, only 2 were with the recipient's original intended living donor. Four (80%) of the positive crossmatch transplant recipients received plasmapheresis immediately before transplant to achieve a BFXM less than 300 (mean BFXM of 209 [SD, 81] ). Patient and graft survival is 100% at a mean follow-up of 815 (SD, 732) days.
DISCUSSION
Therapy to reduce alloantibody is an unmet need in transplantation. Bortezomib has been the subject of much interest in this area, but data establishing its clinical efficacy is limited. 23, 24 Our current study shows that 32 doses of BTZ monotherapy given to a highly sensitized patient cohort resulted in only a modest reduction in both class I and II antibodies at various MFI levels, but it is not well tolerated. However, it is unlikely that the decrease in antibody was clinically meaningful because no consistent change in cPRA at various MFI levels was detected, and none of the patients achieved a BFXM that was considered acceptable for transplantation with their original intended donor (BFXM <300). Ultimately, 80% of the patients in this cohort did receive a KTx, but it is unknown whether their chance for transplantation was increased because of this therapy. The patient's cPRA was unchanged with therapy, but there was a modest decrease in the number of unacceptable antigens per patient. However, most patients waited nearly 3 years after therapy for a transplant. Our findings are consistent and extend the findings of our own work and the work of others. 25, 26 Importantly, in the current study, we found that before BTZ treatment, antibody levels were stable. Thus, any reduction in alloantibody was likely due to treatment and not due to chance variability. This therapy may have been more effective in a less sensitized patient cohort, but the highly sensitized cohort we targeted is the most in need of therapy. National registry data show that despite the new kidney allocation system in the United States, 6% of the patients on the deceased donor waitlist have a cPRA of 100%.
1 These patients have the longest transplant waiting time and are subject to increased morbidity and mortality on dialysis. Less sensitized patients are more likely to receive benefit from paired donor programs 27 or recent changes from the kidney allocation system.
The reasons for the limited efficacy remain unclear. In vivo, normal PCs may be more resistant to proteasome inhibition than myeloma cells (ie, malignant plasma cells). 28 It is also possible that combining BTZ with other agents or plasmapheresis might increase its efficacy in a manner similar to combination therapy has been shown to improve its efficacy in myeloma. 29 Bortezomib combined with other therapy is associated with a reduction in anti-HLA antibodies in a less sensitized patient cohort. 30 In that cohort, it remains unclear how much of the treatment effect was from BTZ or the other therapies used (ie, plasmapheresis). Other approaches to PC depletion with blockade of IL-5 or IL-6 are areas are of particular interest.
Our study was limited because it was nonrandomized and small. It is possible that we did not have enough power to detect a significant change in cPRA or flow cytometric crossmatch. It is important to emphasize that although there was no change in cPRA, there was a decrease in the total number of the unacceptable antigens posttreatment, which could have increased the access to transplantation for some patients. Another limitation of our study was the quantification of anti-HLA antibody. We performed 1 serum dilution to detect bead saturation, but we did not obtain antibody titers. Determining the change in the antibody titer as opposed to examining the MFI alone may have provided more information about the actual change in antibody level, but it is unlikely that this information would change clinical management. Most of the antibody levels remained too high for negative crossmatch transplantation regardless of treatment.
In conclusion, up to 32 doses of BTZ monotherapy is associated with a decrease in anti-HLA antibodies, but we do not recommend it routinely for desensitization. This therapy was not well tolerated, and the reduction in antibody did not appear to translate into important clinical outcomes such negative crossmatch KTx or even a reduction in cPRA.
